Skip to content

US · GANX · BIOTECHNOLOGY

Gain Therapeutics, Inc. (GANX) intrinsic value and stock valuation

$1.00as of 2026-11-21 · Mkt cap 77.63M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Gain Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values GANX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from GANX’s statements →

Gain Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Bethesda, MD 20814 gaintherapeutics.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$0.00
20182025
Net income
-$-20.16M
20182025
Free cash flow
-$-18.47M
20182025
Total equity
$18.6M+24.5% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$0.00$0.00$60K$140K$160K
Operating income-$-18.71M-$-20.35M-$-22.25M-$-17.78M-$-13.83M
Net income-$-20.16M-$-20.41M-$-22.27M-$-17.59M-$-13.89M
EPSd-$-611.46K-$-892.05K-$-1.71M-$-1.48M-$-1.37M
Operating cash flow-$-18.47M-$-18.87M-$-18.87M-$-14.69M-$-12.37M
Capital expenditure$0.00-$-20K-$-20K-$-120K-$-90K
Free cash flow-$-18.47M-$-18.9M-$-18.88M-$-14.81M-$-12.46M
Total assets$22.8M$12.1M$18.6M$24.1M$39M
Total debt$730K$650K$1.03M$1.27M$1.61M
Net debt-$-20.11M-$-9.73M-$-10.77M-$-6.04M-$-35.27M
Total equity$18.6M$7.34M$12.6M$18.9M$34.8M
Cash and short-term investments$20.8M$10.4M$16.8M$20.1M$36.9M
Income statement
20252024202320222021
Revenue$0.00$0.00$60K$140K$160K
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$60K$140K$160K
Research and development expenses$10.2M$10.8M$11.5M$8.38M$7.16M
Selling, general and administrative expenses$8.5M$9.56M$10.8M$9.54M$6.83M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$18.7M$20.4M$22.3M$17.9M$14M
Cost and expenses$18.7M$20.4M$22.3M$17.9M$14M
Interest income$240K$360K$490K$380K$10K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$90K$80K$80K$60K$20K
Ebitda-$-19.21M-$-19.79M-$-22.1M-$-17.43M-$-13.87M
Operating income-$-18.71M-$-20.35M-$-22.25M-$-17.78M-$-13.83M
Total other income/expenses, net-$-590K$480K$60K$280K-$-60K
Income before tax-$-19.3M-$-19.87M-$-22.19M-$-17.5M-$-13.89M
Income tax expense$860K$540K$80K$90K$0.00
Net income-$-20.16M-$-20.41M-$-22.27M-$-17.59M-$-13.89M
Weighted average shares outstanding$33M$22.9M$13M$11.9M$10.2M
Weighted average diluted shares outstanding$33M$22.9M$13M$11.9M$10.2M
Balance sheet
20252024202320222021
Cash and short-term investments$20.8M$10.4M$16.8M$20.1M$36.9M
Net receivables$800K$770K$240K$100K$200K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$22.2M$11.6M$17.8M$21.1M$37.7M
Property, plant and equipment, net$410K$320K$590K$800K$1.01M
Goodwill and intangible assets$100K$130K$190K$210K$200K
Long-term investments$40K$30K$30K$1.94M$30K
Total non-current assets$580K$520K$830K$3.01M$1.26M
Total assets$22.8M$12.1M$18.6M$24.1M$39M
Accounts payable$830K$950K$1.32M$1.63M$560K
Short-term debt$220K$270K$350K$340K$320K
Deferred revenue$0.00$250K$1.12M$60K$270K
Total current liabilities$3.35M$3.91M$4.95M$4.13M$2.55M
Long-term debt$510K$380K$680K$940K$1.29M
Deferred revenue, non-current$0.00$50K$90K$0.00$0.00
Total non-current liabilities$900K$870K$1.08M$1.09M$1.61M
Capital lease obligations$330K$210K$460K$670K$910K
Total liabilities$4.25M$4.78M$6.03M$5.22M$4.17M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-101.36M-$-81.19M-$-60.78M-$-38.52M-$-20.93M
Accumulated other comprehensive income (loss)$780K-$-250K$250K$40K-$-90K
Total equity$18.6M$7.34M$12.6M$18.9M$34.8M
Total investments$40K$30K$5.03M$14.8M$30K
Total debt$730K$650K$1.03M$1.27M$1.61M
Net debt-$-20.11M-$-9.73M-$-10.77M-$-6.04M-$-35.27M
Cash flow statement
20252024202320222021
Net income-$-20.16M-$-20.41M-$-22.27M-$-17.59M-$-13.89M
Depreciation and amortization$90K$80K$80K$60K$20K
Stock-based compensation$1.8M$2.39M$3.26M$1.53M$840K
Change in working capital-$-1.01M-$-1.08M$440K$1.51M-$-330K
Accounts receivable$0.00$0.00$0.00$0.00-$-60K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-470K$270K-$-640K$1.07M-$-520K
Net cash provided by operating activities-$-18.47M-$-18.87M-$-18.87M-$-14.69M-$-12.37M
Investments in property, plant and equipment$0.00-$-20K-$-20K-$-120K-$-90K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00$4.98M$10.2M-$-14.77M-$-90K
Common stock issued$28.5M$13.2M$12.7M$0.00$42.6M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$28.5M$13M$12.6M-$-80K$41.8M
Net change in cash$10.5M-$-1.41M$4.49M-$-29.57M$29.4M
Cash at end of period$20.9M$10.4M$11.8M$7.34M$36.9M
Operating cash flow-$-18.47M-$-18.87M-$-18.87M-$-14.69M-$-12.37M
Capital expenditure$0.00-$-20K-$-20K-$-120K-$-90K
Free cash flow-$-18.47M-$-18.9M-$-18.88M-$-14.81M-$-12.46M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Gain Therapeutics, Inc.

        Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins. Subsequently, Gain Therapeutics identifies proprietary small molecules designed to bind to these locations, thereby restoring correct protein conformation and alleviating the disease. Their current development pipeline includes several structurally targeted allosteric regulator candidates aimed at combating a range of diseases, such as Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1. Established in 2017, the company is headquartered in Bethesda, Maryland.

        CEO
        Gene Mack
        Employees
        21
        Beta
        0.20

        Explore

        Frequently asked questions

        What is the intrinsic value of Gain Therapeutics, Inc. (GANX)?

        InvestorsCraft does not currently publish an intrinsic value for GANX. How the IC value is calculated.

        Is GANX undervalued?

        InvestorsCraft does not publish an undervaluation signal for GANX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.